1. Opening Hook

Influx Healthtech’s maiden earnings call felt like a startup pitch disguised as a balance sheet. Fresh from its IPO, management arrived armed with confidence, capex plans, and a very specific obsession with capsules, kibbles, and beverages. While most CDMOs talk about scale “over time,” Influx prefers timelines that end with “FY29, easily.”

Margins expanded, cash piled up, and debt stayed missing — a rare combo in manufacturing. But beneath the glossy growth story lies a familiar tension: nutraceuticals still pay the bills, veterinary is still a promise, and ₹500 crore revenue is still PowerPoint, not production.

Still, when a promoter confidently says “we launch two products a day,” you listen. Read on — because ambition here is running faster than installed capacity.

2. At a Glance

• Revenue up 39% – Growth clearly didn’t read the small-cap slowdown headlines.
• EBITDA up 61% – Operating leverage finally showed up to work.
• EBITDA margin 22% – Expanded 302 bps without creative accounting.
• PAT up 78% – Bottom line sprinting harder than topline.
• Cash surplus ₹36.6 cr – IPO money patiently waiting its turn.
• Debt-free status – Old-school conservatism, new-age valuation dreams.

3. Management’s Key Commentary

“This is our maiden earnings call.”
(Translation: please excuse the overconfidence 😏)

“We launch approximately two new products every day.”
(Speed dating, but with formulations)

“All capacity expansion was funded through internal accruals.”
(IPO money still sipping coconut water)

“We aim to double the business by FY27 with similar margins.”
(Aggressive, but said very calmly)

“Veterinary today is like nutraceuticals in 2010.”
(Early-stage optimism unlocked 🐶)

“We can reach ₹450–500 crore revenue by FY29.”
(Factories loading… patience required)

4. Numbers Decoded

Metric                     H1FY26        YoY Change
---------------------------------------------------
Revenue                    ₹66.8 cr      +39%
EBITDA                     ₹14.7 cr      +61%
EBITDA Margin              22.0%         +302 bps
PAT                        ₹10.0 cr      +78%
PAT Margin                 15.0%         +329 bps
Cash & Investments         ₹36.6 cr       Healthy
Capex (H1)                 ₹11.7 cr       Ongoing

• Margins are solid for a CDMO, especially at this scale.
• Cash flow from operations is still modest — expansion eats before it earns.
• Balance sheet strength is real, not cosmetic.

5. Analyst Questions (Decoded)

• “Why is 90% revenue still nutraceuticals?”
  Answer: Because that’s where 23 years of muscle memory sits.
• “Can margins sustain at this level?”
  Management: Yes — and maybe go higher if cosmetics behave.
• “How will you double revenue with 90% utilisation?”
  Answer: Capacity numbers quietly changed